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Introduction
Glucosamine is an amino sugar that is essential for the 
biosynthesis of glycosylated proteins and lipids. It is a 
major constituent of extracellular matrix macromolecules 
such as glycosaminoglycans (GAGs), glycolipids and 
glyco proteins in its acetylated form. It is present in high 
quantities in articular cartilage, intervertebral disc and 
synovial ﬂ uid [1]. Glucosamine can also be extracted 
from the chitosan and chitin exoskeleton of crustaceans 
such as shellﬁ sh and may be stabilized as a salt, glucosa-
mine hydrochloride or glucosamine sulfate for oral 
adminis tration. It has been used for many years in the 
treatment for osteoarthritis (OA). In Europe it is a 
registered drug approved for the treatment of OA (mainly 
for its symptomatic, slow acting eﬀ ect in promoting 
cartilage and joint health). It has been designated an ‘over 
the counter’ dietary supplement by the US Food and 
Drug Administration.
Glucosamine was ﬁ rst thought to provide building 
blocks (substrates) for the biosynthesis of cartilage 
extracellular matrix. Subsequent investigations have 
found further explanations for its anti-inﬂ ammatory and 
anti-catabolic mechanisms of action. In vitro and in vivo
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studies have detailed diﬀ erent lines of evidence for how 
glucosamine can act on joint tissues from OA patients. In 
addition, many clinical trials have demonstrated various 
degrees of eﬃ  cacy for glucosamine in OA patients. Based 
on the published data, the Osteoarthritis Research 
Society International (OARSI) [2,3] and the European 
League Against Rheumatism (EULAR) [4,5] have recom-
mended the use of glucosamine sulfate for the manage-
ment of knee and hip OA. In contrast, the American 
College of Rheumatology (ACR) [6] and the UK National 
Institute for Health and Clinical Excellence (NICE) have 
not recommended glucosamine in the management of 
OA (Table 1). None of the current guidelines have recom-
mended the use of glucosamine hydrochloride, only 
glucosamine sulfate. Finally, it is important to point out 
that OARSI recommends that treatment with glusos-
amine sulfate is discontinued if no symptomatic response 
is apparent within 6 months of use. OA recommendations 
are outlined in Table  1. More recently, a change in 
evidence following a systematic cumulative update of 
research published through January 2009 has been 
reported by OARSI’s treatment guidelines committee [7]. 
Th is meta-analysis reported a gradual decrease in the 
eﬀ ect size (ES) when evidence from randomized con-
trolled trials (RCTs) was chronologically evaluated. Th e 
study highlighted the controversy surrounding the 
eﬃ  cacy of glucosamine in terms of both pain and struc-
ture modiﬁ cations. Th e meta-analysis has highlighted the 
heterogeneity of outcomes in the diﬀ erent RCTs and the 
presence of publication bias. From a scientiﬁ c perspec-
tive, the new concerns raised by the recent meta-analyses 
will undoubtedly stimulate a re-evaluation of the mecha-
nistic eﬀ ects of glucosamine.
Th e use of glucosamine in the management of OA 
remains controversial and its speciﬁ c mechanism of 
action in OA pain and function modiﬁ cation are still 
unclear. Th e objective of this review is to address the 
question raised in the title: is glucosamine still an option 
in the management of OA? Th is review summarizes the 
eﬀ ects of glucosamine in OA based on in vitro and in vivo 
results as well as recent clinical trials. Special attention is 
given to the pharmacokinetics of glucosamine, its side 
eﬀ ects and the diﬀ erences observed with diﬀ erent 
formulations and combination therapies. Finally, based 
on these observations, a conclusion is drawn on the role 
of glucosamine in the management of OA in the context 
of new compounds and new combinations.
Update on in vitro data
Th e anabolic eﬀ ects of glucosamine were primarily 
thought to be attributable to its capacity for providing 
building blocks for the synthesis of GAGs by chondro cytes 
[8-10]. Other eﬀ ects have also been reported, how ever, 
such as its anti-catabolic potency, seen by its inhibition of 
the expression and/or activity of catabolic enzymes such as 
phospholipase A2, matrix metallo protein ases or aggrecan-
ases [11,12]. Another study con ﬁ rmed the potency of 
glucosamine to inhibit the expres sion and activity of 
aggrecanase-2 (a disintegrin and metalloproteinase with 
thrombospondin motifs 5 (ADAMTS-5)) in transiently 
transfected cell lines [13]. Th e authors suggested that the 
symptomatic and functional eﬀ ects of glucosamine 
would be justiﬁ ed by the fact that glucosamine interferes 
with the matrix metalloproteinases responsible for 
proteo glycan degradation in OA.
Various properties were demonstrated for glucosamine 
in the three main tissues involved in OA, cartilage, 
synovial membrane and subchondral bone. Th e main 
potencies were shown in articular chondrocytes, where 
glucosamine was demonstrated to reverse the deleterious 
eﬀ ects of IL-1β [11,14,15]. In rat and human chondro-
cytes, the glucosamine eﬀ ect was shown to occur through 
the inhibition of NF-κB signaling [16,17]. Th e reversal of 
the eﬀ ects of IL-1β in human chondrocytes also inhibited 
Table 1. Recommendations for the use of glucosamine in the management of osteoarthritis
 Reference  Recommendation
OARSI [2,3,7]  ‘Treatment with glucosamine and/or chondroitin sulphate may provide symptomatic benefi t in patients with knee 
   OA. If no response is apparent within 6 months treatment should be discontinued’
EULAR [5] Knee OA ‘There is growing evidence to support the use of two of these agents for their symptomatic eff ects - namely, 
   glucosamine sulphate (1A) and chondroitin sulphate (1A), but for the others the evidence is weak or absent’
 [4] Hip OA ‘SYSADOA (glucosamine sulphate, chondroitin sulphate, diacerhein, avocado soybean unsaponifi able, and hyaluronic 
   acid) have a symptomatic eff ect and low toxicity, but eff ect sizes are small, suitable patients are not well defi ned, and 
   clinically relevant structure modifi cation and pharmacoeconomic aspects are not well established’
ACR [6]  ‘While a number of studies support the effi  cacy of both glucosamine and chondroitin sulfate for palliation of joint 
   pain in patients with knee OA, the subcommittee believes that it is premature to make specifi c recommendations 
   about their use at this time because of methodologic considerations, including lack of standardized case defi nitions 
   and standardized outcome assessments, as well as insuffi  cient information about study design in a number of these 
   published reports’
NICE [81]   ‘The use of glucosamine or chondroitin products is not recommended for the treatment of osteoarthritis’
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; NICE, National Institute for Health and Clinical Excellence; OA, osteoarthritis; 
OARSI, Osteoarthritis Research Society International.
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inﬂ ammatory enzymes, such as the inducible form of 
nitric oxide synthase and cyclooxygenase-2 [18]. Th is 
eﬀ ect of glucosamine was further detailed by Imagawa 
and co-workers [19], who were able to demonstrate that 
glucosamine prevents the demethylation of speciﬁ c CpG 
sites in the IL-1β promoter, consequently preventing the 
expression of IL-1β.
A recent pharmacoproteomic study revealed that 
glucos amine (10 mM) diﬀ erentially regulates the pattern 
of expression of IL-1β-induced proteins in human 
articular chondrocytes [20]. Th e proteins aﬀ ected by 
glucosamine are mainly involved in the signal trans-
duction pathways, redox and stress response, protein 
synthesis and protein folding. In addition, glucosamine 
increased the expression of the GRP78 chaperone 
protein. Th is observation supports the reported anti-
inﬂ am matory eﬀ ect of glucosamine. Th is study also com-
pared glucosamine to chondroitin sulfate; these 
compounds produced diﬀ erent patterns of protein 
modiﬁ cation when tested alone or in combination [20]. A 
synergistic eﬀ ect for the modiﬁ cation of superoxide 
dismutase expression was demonstrated when cells were 
exposed to both compounds, implying a potent eﬀ ect on 
oxidative stress in addition to the modulation of energy 
production and metabolic pathways produced by chon-
droitin sulfate.
Th e pro-anabolic eﬀ ects of glucosamine were demon-
strated in both human chondrocytes and synovial cells, 
where glucosamine was shown to induce the production 
of hyaluronic acid (HA) and to directly enter the GAG 
biosynthetic pathway (that is, for the production of HA, 
keratan sulfate and sulfated GAGs) [21]. Th e authors also 
proposed that the chondroprotective eﬀ ect of glucosa-
mine results from the modulation of enzymes responsible 
for HA synthesis.
Th e potential of glucosamine to induce HA production 
in the synovial membrane was previously suggested in a 
study that used synovial explants [22]. In addition, 
cationic glucosamine derivatives were shown to produce 
an anti-inﬂ ammatory eﬀ ect through the inhibition of 
mitogen-activated protein kinase signaling pathways in 
lipopolysaccharide-stimulated macrophages [23].
Glucosamine sulfate was also shown to be eﬀ ective in 
human OA osteoblasts [24]. Glucosamine increased the 
osteo protegrin/receptor activator of nuclear factor 
kappa-B ligand (RANKL) ratio and reduced bone 
resorption. Th is eﬀ ect was increased when glucosamine 
was used in combination with chondroitin sulfate.
It is important to point out that these studies were 
performed in diﬀ erent culture systems, with various 
formulations and concentrations of glucosamine. Th e 
details of the culture systems and the formulations are 
provided in Table  2. Th e concentrations used in the in 
vitro studies were ‘super physiological’ - in some cases up 
to 2,000 times higher than the maximal concentration 
that can realistically be achieved in plasma (10 μM) after 
oral administration of 1,500 mg of glucosamine sulfate in 
human subjects. Furthermore, some of these studies 
compared the eﬀ ects of two formulations of glucosamine 
in order to provide evidence for the superiority of one or 
another [21,22,25,26]. It was proposed that the diﬀ er-
ences, if they truly existed, might contribute to the 
diﬀ erent results observed in clinical trials with various 
glucosa mine formulations. For example, glucosamine 
sulfate was shown to be a stronger inhibitor of gene 
expres sion than glucosamine hydrochloride [25]. Both 
formulations were commercially available from a lab 
supplier. Th e same group compared glucosamine hydro-
chloride to N-acetylglucosamine [22] and observed no 
eﬀ ect of N-acetylglucosamine on HA production whereas 
glucosamine hydrochloride appeared to modulate this 
parameter. Th e same conclusion was reached in the study 
by Igarashi and colleagues [21]. In contrast, another study 
compared the eﬀ ect of native glucosamine and N-
acetylglucosamine on the metabolic activity of human 
articular chondrocytes [26]. Both compounds exhibited 
diﬀ erent potencies on glucose transport, and GAG and 
HA synthesis. Indeed, N-acetylglucosamine appeared to 
accelerate the facilitated glucose uptake and increase 
both GAG and HA synthesis, suggesting that N-acetyl-
glucosamine may be more eﬃ  cient than native glucosamine.
Glucosamine has also been tested in combination with 
chondroitin sulfate in vitro. Some of the results have 
already been discussed above [20,24]. Th e eﬀ ect of 
combinations of glucosamine and chondroitin was also 
reported by Chan and colleagues [27-30]. Glucosamine 
hydrochloride was tested in combination with chondroitin 
sulfate on bovine cartilage explants. Th e combination 
was shown to inhibit both inﬂ ammatory and catabolic 
intermediates and was slightly superior to glucosamine 
alone [27,28].
Finally, some authors have studied the contribution of 
exogenous glucosamine to the synthesis of chondroitin 
sulfate in human articular chondrocytes in culture [31]. 
Th ey concluded that exogenous glucosamine cannot 
stimulate the synthesis of chondroitin sulfate. Further-
more, they showed that glucose can increase endogenous 
glucosamine to reach concentrations superior to those 
achieved after oral administration.
In conclusion, many of the in vitro investigations 
carried out so far have been performed using high 
concentrations of glucosamine - concentrations that are 
unlikely to be achieved in plasma with oral doses of the 
drug. Several authors have proposed that the therapeutic 
doses used did not allow the identiﬁ cation of proteo-
glycan synthesis as a mechanism of action of glucosamine 
[31,32]. Th erefore, extrapolation of the in vitro data to the 
in vivo situation should be done with great caution.
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Update on in vivo data
Several recent in vivo studies using diﬀ erent animal 
models have demonstrated varying potencies for glucosa-
mine in OA. Glucosamine sulfate (200 and 400 mg/kg/day) 
was tested in the STR/ort mouse model of spon taneous 
OA [33]. Glucosamine was shown to delay the progres-
sion and severity of OA cartilage lesions. Another study 
reported the eﬀ ect of glucosamine sulfate (250  mg/kg/
day) administered to rats after anterior cruciate ligament 
transection (ACLT) [34]. Th e glucosamine treatment 
group showed a lower level of cartilage degradation and 
synovial inﬂ ammation compared to the control group. 
Glucosamine was also shown to modify nociception in 
OA rats. Mechanical allodynia and weight-bearing 
distribution were signiﬁ cantly improved by the treatment 
with glucosamine. In addition, the authors showed that 
glucosamine aﬀ ected mitogen-activated protein kinase 
signaling in articular chondro cytes by inhibiting p38 and 
JNK expression while increas ing Erk1/2 expression.
Th e eﬀ ect of glucosamine on cartilage degradation, 
synovial inﬂ ammation and bone resorption was recently 
tested in a model of collagenase-induced OA [35]. Th is 
study also compared the eﬃ  cacies of glucosamine 
hydrochloride and glucosamine sulfate. Th e authors 
showed a better eﬃ  cacy for glucosamine hydrochloride 
but did not provide any explanation for this diﬀ erence. 
Indeed, glucosamine sulfate demonstrated no eﬀ ect on 
the histological score and the formation of osteophytes 
whereas glucosamine hydrochloride produced a signiﬁ -
cant reduction of these parameters; glucosamine sulfate 
was not further evaluated. However, the results showed 
that glucosamine hydrochloride administered orally to 
OA mice (20  mg/kg/day) inhibited not only the loss of 
GAGs and proteoglycans in articular cartilage but also 
Table 2. Principal characteristics of the in vitro studies testing glucosamine
Model Concentration Results Reference
Glucosamine sulfate   
 Human OA chondrocytes 5-500 μM Inhibition of PLA2 and collagenase in a lesser extent through PKC inhibition [12]
 Human OA chondrocytes stimulated  10-1,000 mg/L Inhibition of NF-κB activation [17]
 with IL-1β  Inhibition of COX-2 expression and synthesis and PGE2 release
 Human chondrocytes stimulated  10 mM Infl uence of the proteomic profi le [20]
 with IL-1β
 Human OA cartilage explants 5 mM Inhibition of catabolic and anabolic gene expression [25]
   Superiority over glucosamine hydrochloride in the same conditions
 Human OA osteoblasts 200 μg/ml Inhibition of pro-resorptive agents [24]
Glucosamine hydrochloride   
 Transfected cell lines 10 mM Inhibition of ADAMTS-5 expression and activity [13]
 Human OA synovium explants 0.5-5 mM Induction of HA production [22]
   No eff ect of N-acetylglucosamine
D(+)-Glucosamine   
 Rat chondrosarcoma cell line and  2-16 mM Inhibition of aggrecanase-dependent cleavage [11]
 bovine cartilage explants
 Rat chondrocytes stimulated with IL-1β 1-4.5 g/L Reversion of IL-1β deleterious eff ect on PG anabolism [14]
 Rat chondrocytes stimulated with IL-1β 4.5 g/L Inhibition of NF-κB [16]
 Rat chondrocytes stimulated with IL-1β 20 mM Inhibition of infl ammatory cytokines, chemokines and growth factors [15]
   Inhibition of MMPs and aggrecanase-1
 Human synovial cells and 0.1-1.0 mM Stimulation of HA and GAG production [21]
 chondrocytes  Stimulation of HA synthase activity
   No eff ect of N-acetylglucosamine
N-acetylglucosamine   
 Human chondrocytes stimulated  10 mM Inhibition of iNOS, COX-2 and IL-6 expression [18]
 with IL-1β
 Human chondrocytes 5-20 mM Increased synthesis of GAG and HA due to acceleration of facilitated  [26]
   glucose uptake
   Superiority over native glucosamine
 Human chondrocytes (normal and  2 mM Prevention of the cytokine-induced demethylation of CpG site in the IL-1β [19]
 OA) stimulated with IL-1β  promoter resulting in decreased expression of IL-1β
ADAMTS-5, a disintegrin and metalloproteinase with thrombospondin motifs 5; COX-2, cyclooxygenase-2; GAG, glycosaminoglycan; HA, hyaluronic acid; 
iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; OA, osteoarthritis; PG, proteoglycan; PKC, protein kinase C; PGE2, prostaglandin E2; PLA2, 
phospholipase A2.
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bone resorption by the inhibition of RANKL through 
downregulation of bone morphogenic protein-2, trans-
form ing growth factor-β3 and pSMAD2 and the up-
regulation of Dickkopf-1 protein levels in the joint. In the 
same study, glucosamine hydrochloride also reduced 
osteophyte formation and was shown to inhibit the 
production of the pro-inﬂ ammatory cytokine IL-6 and to 
upregulate the production of the anti-inﬂ ammatory cyto-
kine IL-10 by the synovial membrane.
Glucosamine hydrochloride was also tested in the rat 
ACLT model of OA [36]. Glucosamine administered at a 
dose of 1,000  mg/kg/day produced a chondroprotective 
eﬀ ect and reduced the serum level of the collagen 
degradation biomarker CTX-II. It was also tested on 
equine synovial inﬂ ammation induced by lipopolysac-
charide injection [37]. Glucosamine hydrochloride was 
administered by nasogastric gavage at a dose of 20 mg/kg. 
Th is study revealed that glucosamine levels were 
increased in the synovium during inﬂ ammation in com-
parison to the healthy joint. Th e authors did not conclude 
if glucosamine produced a therapeutic eﬀ ect or not. Th e 
same group has previously published results comparing 
the pharmacokinetics of glucosamine sulfate to glucosa-
mine hydrochloride in horses [38]. Th ey measured higher 
concentrations of glucosamine in synovial ﬂ uid after 
glucosamine sulfate administration than after glucosa-
mine hydrochloride administration and concluded that 
glucosamine sulfate is better absorbed by the horse. 
Glucosamine hydrochloride was also tested in OA dogs 
in combination with chondroitin sulfate [39]. Th e 
combination of the two compounds reduced pain and 
improved weight bearing as well as reduced disease 
progression.
Glucosamine in the form of N-acetylglucosamine was 
tested in rabbits undergoing the ACLT model of OA [40]. 
N-acetylglucosamine was administered once a week intra-
articularly at a dose of 150  mg/injection. Th is study 
suggested that glucosamine may preserve the integrity of 
articular cartilage but no statistical evidence was 
provided to support this suggestion.
Finally, glucosamine sulfate (500 mg/kg) and a combi-
nation of it with chondroitin sulfate (400  mg/kg) were 
compared in the rat ACLT model of OA [41]. Th e results 
showed the superiority of the combination over 
glucosamine alone in the prevention of biochemical and 
histological cartilage modiﬁ cations that occur in the rat 
OA model.
Glucosamine has produced various eﬀ ects in diﬀ erent 
in vivo models. It has been tested under diﬀ erent 
conditions with diﬀ erent formulations and dosages, 
tending to produce a protective eﬀ ect on articular tissues. 
At this stage it is impossible to conclude whether one 
formulation is superior to another. Th erefore, further 
studies are clearly warranted.
Clinical data
Pharmacokinetic studies
Th e pharmacokinetics of exogenous glucosamine has been 
diﬃ  cult to study since glucosamine is naturally present in 
several biological ﬂ uids. Th e origin of endogenous 
glucosamine, if any, is unknown, although it could be 
speculated that endogenous glucosamine mainly results 
from connective tissue metabolism, since glucosa mine is 
contained in tissues that are not consumed (for example, 
shellﬁ sh exoskeleton). Analytical methods have been 
developed in order to measure glucosamine in human 
plasma [42-44] and synovial ﬂ uid [45]. Most of the 
available data on the pharmacokinetics of glucosa mine 
have been obtained with glucosamine sulfate; few studies 
have been published on the pharmacokinetics of glucosa-
mine hydrochloride in human subjects.
Th e ﬁ rst pharmacokinetic study of glucosamine 
sulfate was done in 12 healthy volunteers (6 females and 
6 males) after repeated oral doses [46]. Glucosamine 
was rapidly absorbed and available in the systemic 
circulation. It reached steady state after 3 hours and the 
maximal plasma concentration was 10  μM after oral 
intake of a standard dose of 1,500  mg. Th e plasma 
concentration was shown to remain above baseline for 
up to 48 hours after oral administration. Th e elimination 
half-life was estimated at 15  hours, on the basis of a 
single oral daily dose. Pharmacokinetics were further 
investigated in 12 OA patients with the same regimen of 
administration [47]. Th is study revealed that glucos-
amine was bio available both in plasma and at the site of 
action, that is, within the joint. Glucosamine reached 
constant and higher levels (up to 25% higher) in the 
synovial ﬂ uid compared to plasma. Selective accumu-
lation was also observed in cartilage after repeated 
administration of glucosamine [48]. Glucosamine was 
found not to bind to plasma proteins and up to 43 to 
47% was associated with blood cells [49]. Th e authors 
concluded that the pharma cologically active fraction of 
glucosamine was the same in plasma and at the site of 
action.
Some information regarding the pharmacokinetics of 
glucosamine hydrochloride has been recently published 
[50]. Th e main purpose of this work was to study the 
inﬂ uence of glucosamine on the pharmacokinetics of 
chondroitin sulfate, although this study did provide a few 
pharmacokinetic parameters for glucosamine hydro-
chloride. Th e authors showed that a single oral adminis-
tration of 1,500 mg led to a maximal plasma concentra-
tion of 492  ±  161  ng/ml (2.28  μM; Cmax) reached in 
2.31 ± 1.19 h (Tmax). After 3 months of multiple dosing, 
Cmax was reduced to 211 ± 93.1 ng/ml (0.98 μM) and Tmax 
was identical at 2.31  ±  1.19  h. In addition, glucosamine 
hydrochloride in combination with chondroitin sulfate 
showed a lower plasmatic level, meaning that chondroitin 
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sulfate inhibits glucosamine hydrochloride absorption 
and decreases its biodisponibility [50].
Glucosamine hydrochloride and sulfate are identical 
from a chemical and structural point of view. Th e 
addition of salt does not justify the diﬀ erence in eﬃ  cacy 
or biological eﬀ ects observed in diﬀ erent studies. Indeed, 
both glucosamine sulfate and hydrochloride dissociate in 
the acidic milieu of the stomach, resulting in the release 
of glucosamine itself [51]. It is important to bear in mind 
that the pharmacokinetic parameters were determined in 
two diﬀ erent systems (administration and analytical 
methods), which could explain the observed diﬀ erences. 
To date, no published study has directly compared the 
two formulations and/or established a rigorous method-
ology for comparison.
Clinical effi  cacy
Glucosamine is classically administered orally to human 
subjects at a dose of 1,500  mg/day. In clinical trials 
involving OA patients it was shown to reduce pain and 
provide functional improvement [52-54] in addition to 
structure-modifying eﬀ ects [55,56]. Several meta-
analyses have summarized the eﬃ  cacy of glucosamine as 
reported from diﬀ erent clinical trials [52,54,57-59]. Th e 
most recent study from Wandel and colleagues [60] 
analyzed the results from randomized trials with an 
average of at least 100 patients with hip or knee OA. Th e 
authors searched databases through to June 2010, 
including the most recent trials [61-64]. Th ey retrieved a 
total of 10 trials (a total of 3,803 patients) that met their 
inclusion criteria. Th eir analysis reported ESs of -0.17 
(-0.28 to -0.05) for joint pain and -0.16 (-0.25 to 0.00) for 
joint space width with glucosamine. Th ey concluded that 
glucosamine produced no clinically relevant eﬀ ect on 
pain or structure. Another recent meta-analysis concen-
trated on the structure-modifying eﬀ ect of glucosamine 
[65]. Th e authors searched databases through 2008. Th ey 
retrieved two trials meeting their criteria with glucosa-
mine and structural modiﬁ cations in OA patients. Th eir 
analysis of joint space narrowing and odds ratios revealed 
that glucosamine sulfate was not eﬀ ective at producing 
structural modiﬁ cations after one year of treatment, but 
glucosamine sulfate produced a small to moderate 
protective eﬀ ect on minimum joint space narrowing after 
three years. It is important to note that this analysis was 
performed using just two trials.
Th e systematic review that is the basis for OARSI 
recommendations for the management of hip and knee 
OA was recently updated using more recent publications 
on glucosamine (until January 2009) [7] and highlighted 
many interesting points. Th e analysis gathered the results 
from 19 RCTs from a total of 20 retrieved placebo-
controlled trials, including the recent ones already men-
tioned above. Sixteen of them used glucosamine sulfate 
preparations (thirteen oral, two intra-muscular and one 
intra-articular) and three of them used glucosamine 
hydro chloride. Th is review revealed a decrease of ES for 
pain evaluated without discrimination between glucosa-
mine preparations from 0.61 (0.28 to 0.95) in 2008 [3] to 
0.46 (0.23 to 0.69) in 2010, corresponding to a moderate 
symptomatic eﬃ  cacy [7]. Th e ES for pain reduction was 
0.58 (0.30 to 0.87) for glucosamine sulfate, whereas it was 
not signiﬁ cant for glucosamine hydrochloride (-0.02 
(-0.15 to 0.11)). However, the analysis revealed that the 
outcomes of trials conducted with glucosamine hydro-
chloride were homogenous, while those conducted with 
glucosamine sulfate were very heterogeneous. When 
con sider ing only high quality trials, the ES for glucosa-
mine sulfate decreased to 0.29 (0.003 to 0.57), with no 
publication bias but still heterogeneity outcomes of trials. 
Th e same analysis revealed a small but signiﬁ cant ES 
(0.24 (0.04 to 0.43)) for glucosamine sulfate for reduction 
of joint space loss in the medial compartment of knee OA 
patients, as reported by two sponsored RCTs [55,56], but 
a non-signiﬁ cant eﬀ ect on joint space narrowing in hip 
OA patients after a 24-month treatment either when 
considering the whole study group [66] or when analyz-
ing predeﬁ ned subgroups for OA severity [64]. Th e same 
conclusion was reached by the Glucosamine/Chondroitin 
Arthritis Intervention Trial (GAIT), with a ES of 0.15 
(-0.07 to 0.38) [61]. In addition, this trial did not validate 
the conclusion of a study by Bruyere and colleagues [67] 
that glucosamine sulfate (1,500 mg/day) taken for at least 
12  months reduces by half the incidence of total knee 
replacement, since the decision for surgical intervention 
is inﬂ uenced by many factors. Th e structure-modifying 
eﬀ ect of glucosamine on OA joints remains controversial.
Two clinical trials have been published since the 
publications of these meta-analyses. Th e results of the 
ﬁ rst one by Sawitzke and colleagues [68] were in line with 
the previously mentioned analysis and reported no 
signiﬁ cant diﬀ erence in the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC) 
pain or function score with glucosamine compared to 
placebo. Th e second one by Petersen and colleagues [69] 
studied a diﬀ erent outcome: the serum level of cartilage 
oligomeric matrix protein, a marker of cartilage degrada-
tion. Th is studied showed that combined with exercise, 
glucosamine sulfate treatment reduced the level of serum 
cartilage oligomeric matrix protein.
Meta-analyses have revealed the heterogeneity of out-
come measures and the presence of publication bias 
[2,3,7]. Th e most recent analysis by Wandel and colleagues 
[60] conﬁ rms this. Th e analysis reported that the esti-
mated diﬀ erences between placebo and studied supple-
ments were less pronounced in industry-independent 
trials compared to industry-sponsored trials. However, 
the retrieved trials in this analysis demonstrated less 
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heterogeneity. Th e quality of clinical trials, including 
study design, number of patients, outcome measures and 
publication bias, justiﬁ ed the drastic reduction of the ES 
observed for glucosamine over the years and trials.
Finally, the weak eﬀ ect of glucosamine reported by 
clinical trials can be attributed to the low concentrations 
of glucosamine available to joint tissues [51]. Indeed, the 
competition that exists between glucosamine and glucose 
for cellular uptake favors transport of glucosamine in the 
intestine, liver and kidney, leaving little glucosamine 
available for uptake by the joint.
Side eff ects
Glucosamine is considered to be safe, and no serious or 
fatal adverse events have ever been reported from RCTs. 
However, several potential side eﬀ ects have to be kept in 
mind. Th e ﬁ rst and most evident side eﬀ ect of glucosa-
mine that patients should be aware of is shellﬁ sh allergy. 
Indeed, glucosamine is extracted from chitin contained 
in shellﬁ sh and could lead to allergic reactions in certain 
individuals. In addition, glucosamine sulfate is adminis-
tered as a salt, combined with NaCl. Th is formulation 
provides up to 30% of the daily intake of salt. Th is matter 
has to be taken into account since Na+ but also Cl- could 
inﬂ uence blood pressure and renal function in patients 
[70,71]. Finally, some human and animal studies have 
suggested that glucosamine can aﬀ ect glucose metabo-
lism and it has been shown to induce insulin resistance 
[72-75]. Despite the evidence, however, a recent compre-
hensive review supported by a glucosamine manufacturer 
has rejected these statements. Th e authors concluded 
that glucosamine had no eﬀ ect on fasting blood glucose 
levels, glucose metabolism, or insulin sensitivity at any 
oral dose level in healthy subjects, individuals with 
diabetes, or those with impaired glucose metabolism 
[76]. Th e lack of reported adverse events during clinical 
trials could be attributable to the short duration of 
patient exposure to the treatment. Th erefore, long-term 
treatment could be risky for diabetic and/or hypertensive 
patients. For these reasons, many authors recommend to 
monitor blood glucose concentration and blood pressure 
in these patients [73-75,77]. Clearly, further studies are 
warranted to determine the longer term eﬀ ects of 
glucosamine on insulin sensitivity in human subjects.
Conclusion
Diﬀ erent formulations of glucosamine tested in various 
in vitro or in vivo systems have exhibited many potential 
mechanisms of action on articular structures. Further-
more, two of the major published guidelines recommen-
ded glucosamine sulfate in the treatment of OA pain 
while another integrating more recent data did not 
consider glucosamine sulfate. At this time, glucosamine 
hydrochloride cannot be recommended based on the 
available clinical data. However, there are no clear 
indications that the eﬀ ects of the two formulations can be 
distinguished from each other in terms of biological 
activity, posology or pharmacokinetics. Recent meta-
analyses have reminded us of the importance of the 
quality of the clinical trials and this matter is more and 
more frequently addressed in the literature [51]. Th e 
evaluation tools and the design of clinical trials should be 
standardized and there are many ongoing eﬀ orts in this 
area [78].
Finally, it is important to note that the majority of the 
published clinical trials with glucosamine reported a 
signiﬁ cant ratio of subjects who failed to respond to 
treatment. Th erefore, the question of the beneﬁ t of 
glucosa mine treatment remains largely unanswered. One 
may wonder about the clinical relevance of this treatment 
and whether to use it with regards to the cost/beneﬁ t 
ratio. On the one hand, compared to non-pharmaco-
logical modalities such as exercise, weight loss or educa-
tion, glucosamine is not eﬀ ective with regards to pain 
and function, but the question of its cost compared to 
nonpharmacological modalities should be explored. On 
the other hand, glucosamine sulfate shows an ES superior 
to (or at least equal to) the commonly used analgesic or 
nonsteroidal anti-inﬂ ammatory drugs, but has no rare or 
adverse eﬀ ects.
Th erefore, based on the fact that glucosamine has low 
and rare adverse eﬀ ects, it represents a viable option for 
the management of OA (as a symptomatic slow acting 
drug) but its administration should be discontinued if no 
signiﬁ cant eﬀ ect is reported by the patient. New tools, 
such as novel biomarkers, are required to discriminate 
responders and non-responders. Th e use of glucosamine 
associated with the monitoring of response using an 
appropriate biomarker could improve the eﬃ  ciency and 
the cost/beneﬁ t ratio of the treatment. Finally, we should 
consider the use of glucosamine as a combination therapy 
with other drugs or other nutraceuticals, such as omega-3 
fatty acid or manganese ascorbate [79,80]. Th is would 
open up a new horizon in this ﬁ eld but the combinations 
would need to be rigorously assessed.
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